BRAF and cutaneous melanoma: While targeting MAP kinase signaling in cutaneous melanoma with Braf and MEK inhibitors have led to increased survival in cutaneous melanoma [4, 5], similar targeting of signaling pathways lags behind in uveal melanoma.